Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer
Chunni Wang(Lanzhou University of Technology), Bo Han(Peking University), Lin Wang(Zhuzhou Central Hospital), Ning Lü(Hong Kong Baptist University), Weiwei Fu(Shandong University), Weiwei Tan(Shandong University), Bo Su(Hebei University of Technology), Xiaoqing Yang(Shandong University), Jingjing Song(Qingdao University)
Cited by 54
Related Papers
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
|The Lancet Oncology|2020|401
Use of Mobile Health Applications for Health-Seeking Behavior Among US Adults
|Journal of Medical Systems|2016|220
Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma
|Annals of Oncology|2013|126
High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation
|Journal of Experimental & Clinical Cancer Research|2017|94